Greil R, Tedeschi A, Moreno C, Anz B, et al. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Ann Hematol 2021;100:1733-1742.
PMID: 34018029